ESMO20 Preview 4 – Targeted therapies to watch out for

What to watch out for this weekend in targeted therapies and early stage new product development

September 17, 2020

Encouraging progress in immunometabolism

Novel approaches to metabolism may have far-reaching effects on anti-cancer therapies

September 1, 2020

A novel way to target KRAS mutant lung cancer

Rare mutations in lung cancer (STK11/KEAP1) could be associated with defects in cancer metabolism - we look how they impact KRAS mutant lung cancer

August 13, 2020

Building up a storm against resistant solid tumours

Today’s focus is on an emerging new biotech company with potential to make an impact in difficult to…

August 5, 2020

Controversial developments in pancreatic cancer

What can we understand from novel research on the biology of the disease that might lead us to new cancer therapeutics?

July 30, 2020

A new dawn for epigenetic therapy in oncology

A novel epigenetic target may have far-reaching outcomes for cancer patients

July 23, 2020

Solid tumour winners and losers at ASCO20

Highlights from several solid tumour trials in both early and late stage disease.

June 9, 2020

Novel anti-cancer agents to watch out for

A look at five novel anti-cancer agents in early R&D pipelines and what we can learn from their experiences

April 30, 2020

Postcards from Day 1 of AACR20

Commentary on Day 1 of the AACR20 Virtual Meeting

April 28, 2020

Reflections on new developments in the KRAS niche

Beyond KRAS G12C inhibitors, there are plenty of other related targets to consider including KRAS::SOS1 and SHP2

April 20, 2020

When oncology and coronavirus worlds collide

Key RNA transcription factors may have a role to play as therapeutic targets for both cancer treatment and the coronavirus

March 4, 2020

A look at Mirati in the context of the broader KRAS niche

An interview with Mirati's Chuck Baum and Jamie Christensen exploring the evolving opportunities and challenges in the KRAS G12C niche

February 25, 2020

A hidden gem in the KRAS niche

Monotherapy approaches won't be enough to shut down KRAS mutations in solid tumours, so what targets can we add in to reduce acquired resistance?

February 19, 2020

Competition rapidly heats up in the KRAS space!

Overcoming acquired resistance to KRAS inhibitors will be key to success - here's one potential way to do that.

January 20, 2020

The Future of Oncology R&D

Six key strategic factors to consider going forward in the quest for future oncology R&D pipelines

January 6, 2020

Update on the KRAS Runners and Riders

A look at new developments in the KRAS niche and also a potential emerging novel target in addressing the development of acquired resistance.

December 3, 2019

Insights on targeting the oncogene SHP2

How do we improve responses to EGFR, BRAF & KRAS inhibitors? One way may be add in a SHP2 inhibitor - we look at why this target matters and which competitors are in this niche.

October 30, 2019

New path to market opportunity for Kura in SCCHN

KRAS isn't the only RAS mutation seeing progress - there's also HRAS which is now druggable thanks to Kura Oncology's tipifarnib

October 29, 2019

What do we learn from a first look at Mirati’s KRAS G12C inhibitor MRTX849?

Dr Pasi Janne presented the initial first-in-man data from Mirati's KRAS G12C inhibitor MRTX849 - what did we learn?

October 28, 2019

Further issues surrounding RAS inhibition in oncology

On dosing issues, read across from BRAF in CRC, what is SOS1 and a look at future combinations...

October 25, 2019

A novel approach to targeting BRAF and KRAS mutant cancers

How do we go about targeting KRAS mutations beyond G12C? Here's one elegant way that is promising yet very early in which it could be approached...

October 23, 2019

Update on Amgen’s KRAS inhibitor in solid tumours

We saw signs of activity from Amgen's KRAS G12C inhibitor in lung cancer at WCLC so it's time to look at what happens in colorectal cancer.

September 28, 2019

Targeting KRAS – Highlights from WCLC 2019

Barcelona – Gosh, what a weekend chock full of lung cancer data at the World Congress on Lung Cancer…

September 9, 2019

Will bromodomain inhibitors and PROTACs make an impact?

A look at BET-bromodomain inhibitors, PROTACs, stapled proteins and more on MYC

September 4, 2019

Can a new class of agents therapeutically target the MYC or RAS oncogenes?

How do we go about therapeutically targeting deep protein-protein interactions that can cause aberrant cancer activity? Here's one novel approach in early development...

September 3, 2019

A look at Amgen’s early oncology pipeline

Amgen have a large early phase 1 oncology pipeline including bispecifics, BiTEs, a CAR and small molecules. What can we learn from recent data presented?

July 18, 2019

Challenges of targeting KRASG12C and why Amgen’s AMG 510 may not be a winner

Exploring the many challenges associated with targeting KRASG12C and why we should temper enthusiasm for this niche

May 15, 2019

TKIs are still alive and kicking!

Drugging the undruggable with creative approaches to molecule development

January 9, 2019